Adipose tissue is an endocrine organ and a site of estrogen synthesis via the aromatase enzyme (Kuryowicz, 2023)
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
It was developed by Novo Nordisk under the code NNC 26-0161 and taken into clinical study for postoperative ileus, where gastrointestinal motility rather than growth hormone was the endpoint of interest
Conclusion Empagliflozin (Jardiance) has transformed the treatment landscape for type 2 diabetes
However, allulose has multiple safety studies in dogs
Supports GLP-1 pathway naturally